anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
We examined the associations of middle childhood and adolescence nighttime sleep duration with adolescence internalizing and externalizing behavior problems per the Youth Self-Report (YSR) and the Child Behavior Checklist (CBCL) questionnaires, in a cohort of 889 Colombian schoolchildren. We estimated adjusted differences with 95% confidence intervals (CI) in mean behavior problem t-scores in standardized units between recommended sleep duration categories and as a continuous exposure using multiple linear regression and restricted cubic spline models, respectively. Compared with sleep duration within recommendations, middle childhood sleep above recommendations was related to 4.6 (95% CI: 1.6, 7.6; p = .004) and 5.4 (95% CI: 1.2, 9.7; p = .01) adjusted units higher YSR and CBCL externalizing problem scores, respectively. In continuous exposure analyses, this association seemed restricted to children aged ≥11 years. Longer sleep, both in categories and as a continuous exposure, was also associated with increased CBCL internalizing problems. Results did not differ by sex or weekend/weekday sleep. Sleeping under recommendations in middle childhood was not significantly related to behavior problems; nevertheless, shorter sleep in adolescence, in both categorical and continuous scales, was significantly related to behavior problems. In conclusion, behavior problems in adolescence are associated with longer sleep in middle childhood and shorter sleep in adolescence.
885,746. Dispensing liquids by gaseous pressure. SKANDINAVISKA AEROSOL A. B. Feb. 6, 1959, No. 4216/59. Class 102(2). A liquid mixture intended for expulsion from a pressure container comprises a liquid to be sprayed (" active liquid ") and a liquid solution which is substantially insoluble in the active liquid and has the same or about the same specific gravity as the active liquid, the liquid solution consisting of a propellant having a different e.g. higher specific gravity than the active liquid and a second liquid which may also be a propellant.
PURPOSE: To obtain a medicine which can cure the destruction of epidermal cells or keratinocytes caused by drug intoxication and can treat subcortical bleeding accompanied by the destruction and can recover the functions of the epidermal cells weakened by drug intoxication. CONSTITUTION: This skin preparation for external use contains 4, 7, 10, 13, 16, 19-docosahexaenoic acid (DHA) or its salt or its derivative. DHA acts to promote the proliferation of blood vessel smooth muscle cells in the affected skin whereby the cell membranes are inhibited from weakening and stabilized. The dose of DHA to the affected parts is not particularly limited and the content in the preparation is preferably 0.5-5wt.% or 5-50μmg/cm<2> calculated as DHA. The preparation for external use is formulated to a customary carrier to give a suspension, an emulsion, a tincture, hard ointment or soft ointment, linimentum, liquid preparation or semi-liquid preparation and applied parenterally. When dermatitis develops in oral cavity, the preparation is applied topically in the form of soft ointment or tincture.
Salmonella colonization of fowl may be effectively controlled or inhibited using a defined composition of anaerobic bacteria (i.e., probiotic). The probiotic includes a first culture of substantially pure anaerobic bacteria effective for fermenting lactic acid to produce volatile organic acids including acetic, propionic and/or butyric acids. A second culture of at least one anaerobic bacteria effective for fermenting carbohydrates to produce lactic acid is also employed in combination with the above-mentioned first culture. Suitable organisms for use in this first culture include bacteria of the genera Veillonella, Megasphaera, and mixtures thereof. These first and second cultures are administered to the subject fowl in amounts effective for inhibiting Salmonella colonization thereof. In one embodiment, the above-mentioned probiotic may be combined with a conventional feed, providing a novel feed product which may be orally ingested by the fowl.
This arm will receive the intervention. This intervention is access to the SkillFlix for Parents Microskills video library, about 60 minute in duration. The library includes a curriculum covering skills such as seizing teachable moments, talking about identities, and using a conversation tone.
PURPOSE:To obtain a melanin decomposing substance prepared by extracting algae marine such as brown algae, green algae or red algae and a cosmetic having high safety, an agent of preventing fishes and shellfishes from blackening, an agent of keeping vegetables and fruits from blackening, containing the substance. CONSTITUTION:Especially brown algae (e.g. WAKAME seaweed, sea tangle, sea trumpet, Nemacystus decipiens or gulfweed) are roughly extracted with an organic solvent (e.g. lower alcohols or ketones) having low selectivity to raw material marine algae, then with an organic solvent having high selectivity to inorganic substances, the objective components is subjected to partition (water or organic solvent) extraction with an organic solvent (e.g. hexane or chloroform) having high selectivity, treated by column chromatography and impurities are removed to produce a melanin decomposing substance. The melanin decomposing substance suppresses melanogenesis, not only decomposes formed melanin, decolors am but also removes color, smell, viscosity substance, etc.
A skin cleansing device has a base body and a removable cleansing head. The base body houses a vacuum pump and has a mount for connecting to the removable cleansing head. The mount has an opening into the base body and a support surface. The removable cleansing head has a collection portion and a mounting portion. The collection portion defines an inlet and an internal cavity. The mounting portion has a stem defining a channel fluidly connected to the internal cavity. The cleansing head is removably connectable to the base body with the stem being configured to be received in the opening of the mount. The vacuum pump is configured to generate a fluid flow through the internal cavity and the channel into the base body such that a suction force is generated at the inlet.
2\. When Desmopressin Acetate Injection is administered to patients who do not have need of antidiuretic hormone for its antidiuretic effect, in particular in pediatric and geriatric patients, fluid intake should be adjusted downward to decrease the potential occurrence of water intoxication and hyponatremia. (See PRECAUTIONS, Pediatric Use and Geriatric Use.) All patients receiving Desmopressin Acetate Injection therapy should be observed for the following signs or symptoms associated with hyponatremia: headache, nausea/vomiting, decreased serum sodium, weight gain, restlessness, fatigue, lethargy, disorientation, depressed reflexes, loss of appetite, irritability, muscle weakness, muscle spasms or cramps and abnormal mental status such as hallucinations, decreased consciousness and confusion. Severe symptoms may include one or a combination of the following: seizure, coma and/or respiratory arrest. Particular attention should be paid to the possibility of the rare occurrence of an extreme decrease in plasma osmolality that may result in seizures which could lead to coma.
Failure of endochondral ossification due to interruption of the vascular supply to the epiphyseal cartilage is a critical step in the development of osteochondritis dissecans (OCD). Herein we describe the vascular architecture of the distal humeral epiphyseal cartilage in pigs and identify characteristic features that have been associated with sites predisposed to OCD development across species. Distal humeral specimens were harvested from pigs (n = 5, ages = 1, 10, 18, 30, and, 42 days old) and imaged at 9.4T magnetic resonance imaging (MRI) using a 3D gradient recalled echo sequence. The MRI data were processed using a quantitative susceptibility mapping (QSM) pipeline to visualize the vascular architecture. Specimens were also evaluated histologically to identify the presence of ischemic epiphyseal cartilage necrosis (osteochondrosis [OC]-latens) and associated failure of endochondral ossification (OC-manifesta). The QSM data enabled visualization of two distinct vascular beds arising from the perichondrium at the lateral and medial aspects of the distal humeral epiphysis. Elongated vessels originating from these beds coursed axially to supply the lateral and medial thirds of epiphyseal cartilage. At 18 days of age and older, a shift from perichondrial to transosseous blood supply was noted axially, which appeared more pronounced on the lateral side. This shift coincided with histologic identification of OC-latens (30- and 42-day-old specimens) and OC-manifesta (18- and 42-day-old specimens) lesions in the corresponding regions. The vascular anatomy and its evolution at the distal humeral epiphysis closely resembles that previously reported at predilection sites of knee OCD, suggesting a shared pathophysiology between the knee and elbow joints.
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.
Buzzy was placed 3-5 cm above the injection site 60 sec before the injection and used until the procedure was completed. The Buzzy application to all children in this group was done by the second researcher. After the injection, the ice pack was wiped with 70% alcohol and frozen again by freezing.
An environment control system that controls an environment of a subject is provided. The environment control system includes an actuator configured to control an environment of a subject, and a controller configured to control an operation of the actuator. The environment control system includes an inference unit that includes a first learned model and a second learned model. The first learned model has been trained by associating environmental information indicating an environment of a subject with data correlating with one of sleep, excretion, movement, skin, and stress conditions of the subject. The second learned model has been trained by associating the data correlating with one of the sleep, excretion, movement, skin, and stress conditions of the subject with data correlating with a magnitude of one or more risks that may occur with respect to the subject in a future period of time. The environment control system includes an operating condition determining unit configured to, in a case in which data correlating with the magnitude of the one or more risks that may occur with respect to a subject in a future period of time is inferred based on the first and second learned model, evaluate the inferred data to determine an operating condition of the actuator.
BACKGROUND: In free jejunum transfer, knowing the ischemic tolerance time of the jejunum is crucial. It helps determine the need for reharvesting if an unexpected situation prolongs the ischemic time. The current ischemic tolerance time in humans is unknown. We investigated the relationship between ischemic time and postoperative complications in head and neck cancer patients who underwent free jejunum transfer.
METHODS: The study included 76 patients with available medical records out of 103 patients who underwent free jejunum transfer between 2009 and 2023. The association between the surgical procedure, including ischemic time, and patient's background, and flap engraftment, stenosis of the intestinal anastomosis, the swallowing function, and other complications was investigated.
RESULTS: The ischemic time for jejunal flaps ranged from 1 h 24 min to 6 h, with a mean of 197 ± 55.5 min. In 72 patients, the jejunum was successfully engrafted, but vascular occlusion occurred in another four patients. In three of these patients, jejunal necrosis occurred, and there was no specific trend in ischemic time. Stenosis of the intestinal anastomosis occurred in 17 cases (22%), with ischemic time (≥3 h) and age (≥75 years) being significant factors for stenosis (ischemic time: 30% vs. 10%, p = 0.048, age: 50% vs. 15%, p < 0.01). No significant correlations were observed with other complications or the swallowing function.
CONCLUSION: There was no specific trend between ischemic time and jejunal survival rate, indicating that an ischemic time within 6 h may not have affected engraftment. Although we have recently performed intestinal anastomosis prior to vascular anastomosis, the choice of surgical technique should be adapted to the patient's age and background.
<P>PROBLEM TO BE SOLVED: To forcibly release exclusive locks on electronic medical records after a safety check.  <P>SOLUTION: When an electronic medical record to be operated is specified, an exclusive lock check means 14 checks whether the target electronic medical record has been exclusively locked according to exclusive lock management information stored in exclusive lock management information (storage means) 12. If the target electronic medical record has been exclusively locked, an exclusive lock releasability determination means 15 reads out terminal identification information about the terminal device that has exclusively locked the electronic medical record from the exclusive lock management information, and acquires the operation history of the terminal device according to the terminal identification information. The operation history is collated with release restrictions in release restriction (storage means) 13 to determine whether forcible release of the exclusive lock is restricted. If it is not restricted, an exclusive lock release means 16 forcibly releases the exclusive lock on the corresponding electronic medical record.  <P>COPYRIGHT: (C)2007,JPO&INPIT
BACKGROUND: Evidence is emerging that melanoma has distinct aetiologic pathways and subtypes, characterized by factors like anatomic site of the tumour. To explore genetic influences on anatomic subtypes, we examined the extent to which melanomas in first-degree relatives shared the same body site of occurrence.
METHODS: Population-level linked data was used to identify the study population of over 1.5 million individuals born in Western Australia between 1945 and 2014, and their first-degree relatives. There were 1009 pairs of invasive tumours from 677 family pairs, each categorised by anatomic site. Greater than expected representation of site-concordant pairs would suggest the presence of genetic factors that predispose individuals to site-specific melanoma.
RESULTS: Comparing observed versus expected totals, we observed a modest increase in site concordance for invasive head/neck and truncal tumours (P=0.02). A corresponding analysis including in situ tumours showed a similar concordance (P=0.05). No further evidence of concordance was observed when stratified by sex.
CONCLUSION: In conclusion, modest evidence of aggregation was observed but with inconsistent patterns between sites. Results suggest that further investigation into the familial aggregation of melanoma by tumour site is warranted, with the inclusion of genetic data in order to disentangle the relative contributions of genetic and environmental factors.
Because nifedipine decreases peripheral vascular resistance, careful monitoring of blood pressure during the initial administration and titration of Nifediac CC® Extended-release Tablets USP is suggested. Close observation is especially recommended for patients already taking medications that are known to lower blood pressure (see WARNINGS).

This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.
The colon cleansing efficacy and safety of MoviPrep was evaluated in two randomized, actively-controlled, multi-center, investigator-blinded trials in adult patients scheduled to have an elective colonoscopy.

In Study 1, patients were randomized to one of the following two colon preparation treatments: 1) 2 liters of MoviPrep with 1 additional liter of clear liquid split into two doses (during the evening before and the morning of the colonoscopy) and 2) 4 liters of polyethylene glycol plus electrolytes solution (4L PEG + E) split into two doses (during the evening before and the morning of the colonoscopy). Patients were allowed to have a morning breakfast, a light lunch, clear soup and/or plain yogurt for dinner. Dinner had to be completed at least one hour prior to initiation of the colon preparation administration.

The primary efficacy endpoint was the proportion of patients with effective colon cleansing as judged by blinded gastroenterologists on the basis of videotapes recorded during the colonoscopy.

The blinded gastroenterologists graded the colon cleansing twice (during introduction and withdrawal of the colonoscope) and the poorer of the two assessments was used in the primary efficacy analysis.

The efficacy analysis included 308 adult patients who had an elective colonoscopy. Patients ranged in age from 18 to 88 years old (mean age about 59 years old) with 52% female and 48% male patients. Table 3 displays the results.

4L PEG+E’s responder rate was not significantly higher than MoviPrep’s responder rate.

In Study 2, patients were randomized to one of the following two colon preparation treatments: 1) 2 liters of MoviPrep with 1 additional liter of clear liquid in the evening prior to the colonoscopy and 2) 90 mL of oral sodium phosphate solution (90 mL OSPS) with at least 2 liters of additional clear liquid during the day and evening prior to the colonoscopy. Patients randomized to MoviPrep therapy were allowed to have a morning breakfast; a light lunch; and clear soup and/or plain yogurt for dinner. Dinner had to be completed at least one hour prior to initiation of the colon preparation administration.

The primary efficacy endpoint was the proportion of patients with effective colon cleansing as judged by the colonoscopist and one blinded gastroenterologist (on the basis of videotapes recorded during the colonoscopy). In case of a discrepancy between the colonoscopist and the blinded gastroenterologist, a second blinded gastroenterologist made the final efficacy determination. 

The efficacy analysis included 280 adult patients who had an elective colonoscopy. Patients ranged in age from 21 to 76 years old (mean age about 53 years old) with 47% female and 53% male patients. Table 4 displays the results.

MoviPrep’s responder rate was not significantly higher than OSPS’s responder rate.
Despite the widespread adoption of emergency coronary reperfusion therapy, reperfusion-induced myocardial injury remains a challenging issue in clinical practice. Following myocardial reperfusion, S100A8/A9 molecules are considered pivotal in initiating and regulating tissue inflammatory damage. Effectively reducing the S100A8/A9 level in ischemic myocardial tissue holds significant therapeutic value in salvaging damaged myocardium. In this study, HA (hemagglutinin)- and RAGE (receptor for advanced glycation end products)- comodified macrophage membrane-coated siRNA nanoparticles (MMM/RNA NPs) with siRNA targeting S100A9 (S100A9-siRNA) are successfully prepared. This nanocarrier system is able to target effectively the injured myocardium in an inflammatory environment while evading digestive damage by lysosomes. In vivo, migration of MMM/RNA NPs to myocardial injury lesions is confirmed in a myocardial ischemia-reperfusion injury (MIRI) mouse model. Intravenous injection of MMM/RNA NPs significantly reduced S100A9 levels in serum and myocardial tissues, further decreasing myocardial infarction area and improving cardiac function. Targeted reduction of S100A8/A9 by genetically modified macrophage membrane-coated nanoparticles may represent a new therapeutic intervention for MIRI.
Idiopathic pulmonary fibrosis (IPF) is one of the most fatal chronic interstitial lung diseases with unknown pathogenesis, current treatments cannot truly reverse the progression of the disease. Pulmonary macrophages, especially bone marrow derived pro-fibrotic macrophages, secrete multiple kinds of profibrotic mediators (SPP1, CD206, CD163, IL-10, CCL18…), thus further promote myofibroblast activation and fibrosis procession. IL20Rb is a cell-surface receptor that belongs to IL-20 family. The role of IL20Rb in macrophage activation and pulmonary fibrosis remains unclear. In this study, we established a bleomycin-induced pulmonary fibrosis model, used IL4/13-inducing THP1 cells to induce profibrotic macrophage (M2-like phenotype) polarization models. We found that IL20Rb is upregulated in the progression of pulmonary fibrosis, and its absence can alleviate the progression of pulmonary fibrosis. In addition, we demonstrated that IL20Rb promote the activation of bone marrow derived profibrotic macrophages by regulating the Jak2/Stat3 and Pi3k/Akt signaling pathways. In terms of therapeutic strategy, we used IL20Rb neutralizing antibodies for animal administration, which was found to alleviate the progression of IPF. Our results suggest that IL20Rb plays a profibrotic role by promoting profibrotic macrophage polarization, and IL20Rb may become a potential therapeutic target for IPF. Neutralizing antibodies against IL20Rb may become a potential drug for the clinical treatment of IPF.
PROBLEM TO BE SOLVED: To obtain an oil or fat compsn. which inhibits the in-vivo occurrence of a peroxidized fat from an α-linolenic acid-contg. oil or fat and has a synergistic action of α-linolenic and olenic acids on improving serum lipid by mixing an α-linolenic acid-contg. oil or fat with olive oil in a specified ratio. SOLUTION: This oil or fat compsn. contains 100 pts.wt. α-linolenic acid- contg. oil or fat and 50-200 pts.wt. olive oil. Examples of the α-linolenic acid- contg. oil or fat are vegetable oils such as perilla frutescens oil, perilla oil, and edible linseed oil. These oils usually contain about 40-70 wt.% α-linolenic acid. Any rank of olive oil selected from among extra-virgin olive oil, virgin olive oil, pure olive oil, purified olive oil, etc., can be used. If necessary, this compsn. may further contain a spice or an antioxidant such as tocopherol.
Patients are randomized to 2 sequences of 2 treatments. Single 1.5 mg subcutaneous (SC) dose of LY2189265 in Period 1; single intravenous (IV) dose of LY2189265 (determined by Part A IV arm data) in Period 2 or vice versa. There is a washout period of at least 4 weeks between dosing periods.